Home / Stocks / Nectar Lifesciences Ltd.
NECLIFE

Nectar Lifesciences Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹9.98

Change

-0.01 (-0.1%)

Open

₹9.86

Prev. Close

₹9.99

Day High

₹10.28

Day Low

₹9.85

Volume Analysis

Traded

126,918

Delivered

109,032

Delivery %

85.91%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (-31.3%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (28/100)
  • •Low operating margin (-5352.0%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹10.66 ₹10.47 ₹10.23 ₹10.04 ₹9.8 ₹9.61 ₹9.37
Fibonacci ₹10.47 ₹10.31 ₹10.2 ₹10.04 ₹9.88 ₹9.77 ₹9.61
Camarilla ₹10.1 ₹10.06 ₹10.02 ₹10.04 ₹9.94 ₹9.9 ₹9.86

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-51.03%

1 Week

-4.59%

1 Month

-11.6%

3 Months

-4.68%

6 Months

-17.25%

1 Year

-29.57%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-0.0%

Net margin -3300.0% × asset turnover 0.0x × equity multiplier 1.06x

Company Overview

Sector

Healthcare

Market Cap

₹193 Cr

ROE

-31.3%

Book Value

₹29.3

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Nectar Lifesciences Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 28/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-31.3%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

28/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

17

Cash Flow

0

Corporate Governance

43

Momentum

6

Institutional Ownership

20

Business Quality

20

Risk & Volatility

26

Liquidity

50

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Stock is trading at 0.34 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -12.3% over last 3 years.
  • −Contingent liabilities of Rs.269 Cr.
  • −Promoter holding has decreased over last 3 years: -3.96%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Nectar Lifesciences Limited has informed about Copy of Newspaper Publication

Please find attached herewith certificate as per caption regulations

31st AGM minutes: FY26 financials adopted; Sanjiv Goyal reappointed; two independent directors reappointed; Dr. Gunmala Suri appointed.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 398 452 441 359 6 0 0 5 1 0 1 0 0
Expenses + 371 410 393 319 6 0 0 6 0 2 59 28 7
Operating Profit 27 42 49 40 -1 0 0 -1 1 -2 -57 -27 -7
OPM % 6.75% 9.33% 10.99% 11.08% -10.28% -500.0% -500.0% -16.03% 77.46% — -4,437.21% -6,197.73% -66,800.0%
Other Income + 11 0 1 1 7 8 -130 -62 -176 35 -24 3 13
Interest 21 25 24 20 0 0 0 0 0 30 6 0 0
Depreciation 15 15 15 15 0 0 0 1 0 0 0 0 0
Profit before tax 2 2 11 5 5 8 -130 -64 -176 3 -88 -24 6
Tax % 38.41% 36.18% 94.69% 39.63% -2.19% 1.51% -0.05% -0.58% 0.09% -339.08% -22.5% -36.63% 57.7%
Net Profit + 1 2 1 3 6 8 -130 -63 -176 14 -68 -15 3
EPS in Rs 0 0 0 0 0 0 -6 -3 -8 1 -4 -1 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 2 31 14 -9 -99 -100 -100 -99 -88 -100 12,800 -92 -99

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,638 1,674 1,635 1,874 2,779 2,363 1,541 1,665 1,520 1,682 0 0 2
Expenses + 1,371 1,436 1,411 1,638 2,514 2,143 1,432 1,507 1,467 1,530 0 8 95
Operating Profit 267 239 224 236 264 220 109 159 53 152 0 -8 -93
OPM % 16.0% 14.0% 14.0% 13.0% 10.0% 9.0% 7.0% 10.0% 3.5% 9.0% -12.0% -2,920.0% -5,352.0%
Other Income + 20 6 23 6 6 4 -22 11 43 15 -112 -279 28
Interest 126 123 117 115 148 126 112 79 79 87 0 36 36
Depreciation 77 57 62 64 63 61 60 57 59 61 1 0 0
Profit before tax 85 64 67 63 59 37 -85 34 -42 18 -113 -323 -102
Tax % 22.0% 15.0% 18.0% 17.0% 19.0% 15.0% -14.0% 26.0% -43.0% 73.0% 0.0% -9.0% —
Net Profit + 66 54 55 52 48 32 -73 25 -24 5 -114 -293 -66
EPS in Rs 3 2 2 2 2 1 -3 1 -1 0 -5 -15 -4
Dividend Payout % 3.0% 4.0% 2.0% 2.0% 2.0% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 0 2 -2 15 48 -15 -35 8 -9 11 -100 — -71

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 936 932 984 1,036 1,083 1,114 1,040 1,065 1,042 1,047 934 563 550
Borrowings + 925 962 878 955 903 779 903 860 754 636 582 0 0
Other Liabilities + 628 640 696 710 696 718 423 443 371 486 509 39 32
Total Liabilities 2,510 2,556 2,581 2,724 2,705 2,633 2,388 2,391 2,189 2,191 2,047 622 601
Fixed Assets + 934 906 881 852 825 785 772 723 662 643 633 105 105
CWIP 91 99 102 100 100 115 99 85 78 66 57 0 0
Investments 1 1 1 1 1 0 1 1 1 1 1 13 56
Other Assets + 1,485 1,551 1,597 1,771 1,780 1,733 1,517 1,582 1,449 1,482 1,357 504 441
Total Assets 2,510 2,556 2,581 2,724 2,705 2,633 2,388 2,391 2,189 2,191 2,047 622 601
Equity Capital 22 22 22 22 22 22 22 22 22 22 22 19 19

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 144 169 199 65 239 285 21 95 134 225 169 -349
Cash from Investing Activity + -60 -77 -18 -29 -26 -33 -29 17 52 -17 -42 1,208
Cash from Financing Activity + -61 -89 -204 -40 -201 -252 11 -119 -186 -205 -128 -767
Net Cash Flow 23 3 -23 -4 12 0 4 -8 0 2 -1 93
Free Cash Flow 64 87 174 32 204 249 -10 110 183 195 126 -341
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 56 74 92 33 96 134 23 60 252 148 -89,179 4,132

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 55.8% → 51.84%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 28.05% 27.2% 27.57% 40.94% 54.72% 53.64% 54.45% 54.37% 48.73% 43.52% 43.9% 43.74%
Promoters 55.8% 55.8% 55.8% 55.8% 44.53% 44.53% 44.53% 44.91% 44.91% 51.84% 51.84% 51.84%
Government 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 5.84% 4.03% 3.75% 3.92%
FII 16.12% 16.98% 16.6% 3.24% 0.73% 1.65% 0.82% 0.62% 0.52% 0.6% 0.5% 0.5%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.15% 0.19% 0.08% 0.0% 0.01% 0.01% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Nectar Lifesciences Ltd. (this stock) 193 — 0.34 -31.3%
Take Limited 192 22.0 5.6 16.5%
Bilcare Ltd. 202 5.55 1.13 1.39%
Brooks Lab Limited 203 58.7 1.08 22.0%
Balaxi Pharma Ltd 175 51.8 0.69 0.59%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Natural Capsules Limited 144 — 0.66 -9.45%

Which Mutual Funds Hold Nectar Lifesciences Ltd.?

Frequently Asked Questions about Nectar Lifesciences Ltd.

Community Sentiment

What are other investors saying about Nectar Lifesciences Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.